Anticoagulants are a class of drugs that help prevent blood clots. They are commonly called blood thinners. They're given to people at a high risk of getting clots, to reduce the chances of developing serious conditions such as strokes and heart attack. Anticoagulants are commonly used to prevent and treat cardiovascular diseases (CVDs).
Growing prevalence of chronic disease, rise in demand for anticoagulants, increase in focus on the development of novel anticoagulants, and growing geriatric population across the globe are major factors expected to drive growth of the global anticoagulantmarket.
For instance, in June 2022, Apotex Inc. announced the launch of APO-Apixaban tablets, Canada's first generic alternative to Eliquis. Apixaban is an oral anticoagulant indicated for the prevention and treatment of harmful blood clots.
Moreover, in June 2021, the Food and Drug Administration (FDA) approved Pradaxa (dabigatran etexilate) oral pellets to treat children three months to 12 years old with venous thromboembolism. FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.
- This report provides in-depth analysis of the global anticoagulantmarket, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global anticoagulantmarket based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc., Sanofi SA, Dr. Reddy’s Laboratories, Aspen Holdings, Abbott Laboratories, Leo Pharma, Alexion Pharmaceuticals Inc., Bayer AG, Johnson & Johnson, Bristol-Myers Squibb Company, Daiichi Sankyo Company, and Boehringer Ingelheim Pharmaceuticals Inc., among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global anticoagulantmarket report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anticoagulantmarket.
-
- Novel Oral Anticoagulants (NOACs)
- Heparin and Low-molecular- weight Heparin (LMWH)
- Vitamin K Antagonist
-
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism
- Other Applications
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Pfizer Inc.
- Sanofi SA
- Reddy’s Laboratories
- Aspen Holdings
- Abbott Laboratories
- Leo Pharma AS
- Alexion Pharmaceuticals Inc.
- Bayer AG
- Johnson & Johnson
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company
- Boehringer Ingelheim Pharmaceuticals Inc.
